AI in pharma market to hit $28.6b by 2034 on drug discovery push

Asia Pacific is set to post the fastest growth.

The global artificial intelligence in pharmaceutical market is projected to grow to $28.63b by 2034, driven by artificial intelligence (AI)'s expanding role across the drug discovery value chain.

Polaris Market Research said in a report that algorithms now identify drug targets, analyse protein structures, and simulate chemical interactions at a scale conventional lab methods cannot match.

The economics behind the shift are significant: bringing a single drug through clinical trials and FDA approval can cost between $161m and $2b, with only a small fraction of drugs entering trials ultimately succeeding.

That cost-to-success ratio is pushing the industry toward AI-driven approaches aimed at improving success rates and lowering expenses.

By technology, natural language processing led the market with a 35.64% revenue share in 2025, valued for translating complex clinical and biological data into forms usable by medical experts and patients.

Machine learning, deep learning, and generative AI tools are also gaining ground, with generative AI increasingly used to design new molecular structures and predict therapeutic potential.

On deployment, cloud-based services captured the largest market share in 2025, favoured particularly by startups and smaller firms avoiding heavy upfront infrastructure costs.

AI is also reshaping clinical trials, improving patient recruitment through electronic health record and genomic data mining, while predictive analytics help flag risk and refine dosing in real time.

One of the largest opportunities lies in rare and high-burden diseases historically underinvested in due to poor return on development costs. Alzheimer's illustrates the scale—more than 7 million Americans currently live with the disease, and unpaid caregiving in 2024 totalled nearly 19.2 billion hours, valued at over $413b.

Without breakthroughs, the affected population could reach 13.8 million by 2050, with costs approaching $1t.

Regionally, North America led with a 49.80% revenue share in 2025, whilst Asia Pacific is set to post the fastest growth, driven by government-backed AI adoption initiatives in China, India, and South Korea.

Barriers remain, including a shortage of skilled personnel, high implementation costs, and limited acceptance among some healthcare providers.